Stock EXEN EXALENZ BIOSCIENCE LTD
Add to a list
To use this feature you must be a member
Log inSign up

Exalenz Bioscience Ltd Stock

Equities

EXEN

IL0011048688

Medical Equipment, Supplies & Distribution

Delayed TEL AVIV STOCK EXCHANGE
Other stock markets
 		5-day change 1st Jan Change
- ILa -.--% Intraday chart for Exalenz Bioscience Ltd +1.39% +107.88%
2020 Meridian Bioscience, Inc. completed the acquisition of Exalenz Bioscience Ltd from Mori Arkin and others. CI
2020 Meridian Bioscience, Inc. agreed to acquire Exalenz Bioscience Ltd from Mori Arkin and others for approximately ILS 170 million. CI

Financials

Sales 2018 13.14M 3.45M 1.31B Sales 2019 14.04M 3.69M 1.4B Capitalization 77.67M 20.4M 7.77B
Net income 2018 -5M -1.31M -500M Net income 2019 -1M -263K -100M EV / Sales 2018 15.2 x
Net Debt 2018 2.93M 769K 293M Net Debt 2019 3.09M 812K 309M EV / Sales 2019 5.75 x
P/E ratio 2018
-34.6 x
P/E ratio 2019
-40 x
Employees -
Yield 2018 *
-
Yield 2019
-
Free-Float 24.36%
More Fundamentals * Assessed data

Chart Exalenz Bioscience Ltd

Dynamic Chart

Latest news about Exalenz Bioscience Ltd

Meridian Bioscience, Inc. completed the acquisition of Exalenz Bioscience Ltd from Mori Arkin and others. CI
Meridian Bioscience, Inc. agreed to acquire Exalenz Bioscience Ltd from Mori Arkin and others for approximately ILS 170 million. CI
Exalenz Bioscience Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2019 CI
Exalenz Bioscience Receives Approval for Commercial Marketing in China for Its Breathid® HP Lab System CI
Exalenz Bioscience Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018 CI
Exalenz Bioscience Ltd Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2018 CI
Exalenz Bioscience Ltd. Announces BreathID®13C-methacetin Breath Test CI
Exalenz Bioscience Appoints Roy Golan as President and Chief Financial Officer CI
Exalenz Bioscience’s BreathID® Hp & BreathID Hp Lab Systems Receive FDA Clearance for Diagnosis of Helicobacter pylori Testing in Pediatric Patients CI
Exalenz Bioscience Ltd Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017; Provides Earnings Guidance for the Year 2018 and Revenue Guidance for the Year 2019 CI
Exalenz Bioscience Announces Positive Clinical Trial Results for the Diagnosis of Clinically Significant Portal Hypertension in NASH Patients CI
Exalenz Bioscience Ltd Launches Automated BreathID® Hp Lab Urea Breath Testing System For Helicobacter pylori Detection CI
Exalenz Bioscience Plans For Nasdaq IPO CI
Exalenz Bioscience Receives FDA Marketing Clearance for its Laboratory System in the United States CI
Exalenz Bioscience Announces Collaboration with Galectin Therapeutics to Use BreathID to Monitor Patients with Cirrhosis Associated with NASH CI
More news

Press releases Exalenz Bioscience Ltd

Meridian Bioscience : Signs Definitive Agreement to Acquire Exalenz Bioscience; Adds State-Of-The-Art Urea Breath Test Diagnostics Platform AQ
More press releases

Managers and Directors - Exalenz Bioscience Ltd

Managers TitleAgeSince
Raffi Werner CEO
 Chief Executive Officer 65 10-09-30
Moshe Dori DFI
 Director of Finance/CFO - 19-01-28
Eitan Blank COO
 Chief Operating Officer 53 06-12-31
Members of the board TitleAgeSince
Sharon Kochan BRD
 Director/Board Member 55 16-07-03
Moshe Arkin BRD
 Director/Board Member 69 05-12-31
Hanna Lerman BRD
 Director/Board Member 51 15-04-15
More insiders

Company Profile

Exalenz Bioscience Ltd is an Israel-based company active in the medical sector. It develops and commercializes advanced systems that extract vital information for diagnostics from subtle changes in the patient's exhaled breath. Its core technology enables medical specialists to identify and manage specific digestive and liver conditions. The Company's product, the BreathID System, is used for assessment and monitoring of functional diseases of the liver and gastrointestinal tract. The BreathID System is mobile and can be operated in any clinical setting. The Company conducts ongoing research in collaboration with clinical and industrial partners in the United States, Europe, Asia, and Israel.
Sector
Medical Equipment, Supplies & Distribution
More about the company

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
EXALENZ BIOSCIENCE LTD Stock Exalenz Bioscience Ltd
+107.88% 45.97M
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.31% 185B
MEDTRONIC PLC Stock Medtronic plc
-3.20% 105B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.04% 66.59B
DEXCOM, INC. Stock DexCom, Inc.
+0.20% 54.66B
CENCORA, INC. Stock Cencora, Inc.
+17.29% 47.78B
HOYA CORPORATION Stock Hoya Corporation
+4.06% 41.26B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+2.36% 26.95B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.07% 26.37B
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.8B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. EXEN Stock